Telehealth platforms built on selling generic drugs face margin compression from price wars and high customer acquisition costs. Partnering to offer branded, in-demand medications provides a competitive advantage, creating a "gravitational pull" that attracts patients and builds a more defensible business model.
According to a dermatologist CEO, patients seeking prescriptions online via telehealth are a distinct cohort from those visiting a doctor's office. The typical in-clinic patient first tries over-the-counter products, not telehealth solutions, suggesting these channels serve different consumer journeys and largely separate market segments.
Eli Lilly's oral GLP-1 is proving to be a market expander, not just a cannibalizer of injectables. An overwhelming 80% of its users are new to the GLP-1 class, driven by an aggressive direct-to-consumer (DTC) telehealth strategy. This signals a vast, untapped patient population for oral obesity treatments.
Viridermix's strategy for its oral hair loss drug isn't just about convenience. The company re-engineered immediate-release minoxidil to provide consistent exposure to hair follicles, aiming to maximize growth while blunting the plasma spikes responsible for the original blood pressure drug's cardiac side effects.
Unlike publicly traded competitors, Servier's non-profit foundation ownership insulates it from short-term investor pressures. This freedom enables a long-term strategic focus, allowing the company to pursue high-risk, scientifically complex areas like rare oncology that public companies often cannot justify to shareholders.
The FDA's pilot for real-time trial data review could accelerate drug approvals by catching safety signals earlier. However, experts express concern over making premature efficacy judgments based on interim data, especially for long-term outcomes like overall survival, and the potential impact on study blinding.